Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer
详细信息 查看全文
- 作者：Timothy Pricea ; timothy.price@sa.gov.au" class="auth_mail" title="E-mail the corresponding author ; Tae Won Kimb ; Jin Lic ; Stefano Cascinud ; Paul Ruffe ; Attili Satya Sureshf ; Anne Thomasg ; Sergei Tjulandinh ; Xuesong Guani ; Marc Peetersj
- 关键词：Anti-EGFR therapy ; Colorectal cancer ; Gastrointestinal cancer ; Panitumumab
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：68
- 期：Complete
- 页码：51-59
- 全文大小：840 K
文摘
- •
In the ASPECCT final analysis, panitumumab remained non-inferior to cetuximab for overall survival (OS).
- •
Patients who developed hypomagnesaemia had longer median OS versus those who did not.
- •
For panitumumab, OS was longer for those with prior bevacizumab therapy versus those without.
- •
OS/progression-free survival improvement correlated with worse skin toxicity for either anti-epidermal growth factor receptor therapy.